DPP4 and infection: However, preliminary observations from an ongoing phase II trial (NCT02683525) testing sitagliptin for prevention of graft-versus-host disease following peripheral blood stem cell transplantation from matched related and unrelated donors do not suggest that in-vivo DPP-4 inhibition increases the risk of infections (unpublished).